1-(5-isoquinolinesulfonyl)-2-methylpiperazine has been researched along with Amyotrophic Lateral Sclerosis in 4 studies
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine: A specific protein kinase C inhibitor, which inhibits superoxide release from human neutrophils (PMN) stimulated with phorbol myristate acetate or synthetic diacylglycerol.
1-(5-isoquinolinesulfonyl)-2-methylpiperazine : A member of the class of N-sulfonylpiperazines that is 2-methylpiperazine substituted at position 1 by a 5-isoquinolinesulfonyl group.
Amyotrophic Lateral Sclerosis: A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Moreover, fasudil slowed disease progression, increased survival time and reduced motor neuron loss, in SOD1(G93A) mice." | 5.39 | Fasudil, a rho kinase inhibitor, limits motor neuron loss in experimental models of amyotrophic lateral sclerosis. ( Hara, H; Kawasaki, K; Kimura, M; Nagahara, Y; Seto, M; Shimazawa, M; Takata, M; Tanaka, H; Tanaka, K; Tsuruma, K, 2013) |
| "Moreover, fasudil slowed disease progression, increased survival time and reduced motor neuron loss, in SOD1(G93A) mice." | 1.39 | Fasudil, a rho kinase inhibitor, limits motor neuron loss in experimental models of amyotrophic lateral sclerosis. ( Hara, H; Kawasaki, K; Kimura, M; Nagahara, Y; Seto, M; Shimazawa, M; Takata, M; Tanaka, H; Tanaka, K; Tsuruma, K, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Martín-Cámara, O | 1 |
| Arribas, M | 1 |
| Wells, G | 1 |
| Morales-Tenorio, M | 1 |
| Martín-Requero, Á | 1 |
| Porras, G | 1 |
| Martínez, A | 1 |
| Giorgi, G | 1 |
| López-Alvarado, P | 1 |
| Lastres-Becker, I | 1 |
| Menéndez, JC | 1 |
| Takata, M | 1 |
| Tanaka, H | 1 |
| Kimura, M | 1 |
| Nagahara, Y | 1 |
| Tanaka, K | 1 |
| Kawasaki, K | 1 |
| Seto, M | 1 |
| Tsuruma, K | 1 |
| Shimazawa, M | 1 |
| Hara, H | 1 |
| Tönges, L | 1 |
| Günther, R | 1 |
| Suhr, M | 1 |
| Jansen, J | 1 |
| Balck, A | 1 |
| Saal, KA | 1 |
| Barski, E | 1 |
| Nientied, T | 1 |
| Götz, AA | 1 |
| Koch, JC | 1 |
| Mueller, BK | 1 |
| Weishaupt, JH | 1 |
| Sereda, MW | 1 |
| Hanisch, UK | 1 |
| Bähr, M | 1 |
| Lingor, P | 1 |
| Krieger, C | 1 |
| Wagey, R | 1 |
| Lanius, RA | 1 |
| Shaw, CA | 1 |
4 other studies available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Multitarget Hybrid Fasudil Derivatives as a New Approach to the Potential Treatment of Amyotrophic Lateral Sclerosis.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aged; Amyotrophic Lateral Sclerosis; Cell Line, Tumor | 2022 |
Fasudil, a rho kinase inhibitor, limits motor neuron loss in experimental models of amyotrophic lateral sclerosis.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amyotrophic Lateral Sclerosis; Animals; Disease Model | 2013 |
Rho kinase inhibition modulates microglia activation and improves survival in a model of amyotrophic lateral sclerosis.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amyotrophic Lateral Sclerosis; Animals; Astrocytes; A | 2014 |
Activation of PKC reverses apparent NMDA receptor reduction in ALS.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aged; Amyotrophic Lateral Sclerosis; Autoradiography; | 1993 |